Pathogenesis and therapeutic targets in FSHD02/01/2019 - 07/31/2022 (PI)
Muscular Dystrophy Association
Mechanisms of DUX4-mediated FSHD Patholgy01/01/2017 - 06/30/2019 (Subcontract PI)
Nevada System Of Higher Education, dba University of Nevada, Reno NIH NIAMS5R01AR062587-06
Pathogenesis of Muscular Dystrophies05/01/2016 - 04/30/2018 (PI)
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases4R01AR060328-06
Pathogenesis of congenital muscular dystrophy Type 1A(laminin-alpha2-deficiency)08/15/2016 - 02/14/2018 (PI)
Association Francaise Contre les Myopathies
Mechanisms of DUX4-Mediated FSHD Pathology07/01/2016 - 12/31/2016 (Subcontract PI)
University of Massachusetts, Worcester NIH NIAMS4R01AR062587-04
Mechanisms of DUX4-Mediated FSHD Pathology07/03/2013 - 06/30/2016 (Subcontract PI)
University of Massachusetts, Worcester NIH NIAMS5R01AR062587-03
Pathogenesis of Congenital Muscular Dystrophy Type 1A (laminin-alpha2-deficiency)02/03/2015 - 06/19/2016 (PI)
Association Francaise Contre les Myopathies
Pathogenesis of Muscular Dystrophies02/12/2013 - 04/30/2016 (PI)
NIH/National Institute of Arthritis & Musculoskeletal & Skin Diseases5R01AR060328-05
DUX4, epigenetics, and pathogenesis of facioscapulohumeral muscular dystrophy05/23/2014 - 11/22/2015 (PI)
Association Francaise Contre les Myopathies
CMD and LGMD Therapeutics Targets: Studies with patients myogenic cells (MDA216422)02/01/2013 - 07/31/2015 (PI)
Muscular Dystrophy Association
Showing 10 of 12 results.
Show All Results
Evaluating DUX4 as a therapeutic target fpr FSHD03/01/2013 - 01/31/2015 (Subcontract PI)
University of Massachusetts, Worcester Musc Dystrophy Assoc
Project 4: FSHD Biomarkers: Model Studies05/09/2013 - 08/31/2013 (Subcontract PI)
University of Massachusetts Medical School NIH NICHD7U54HD060848-06